Coursera Inc vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? Coursera Inc trades at $5.28 (market cap $1.39B), while Iovance Biotherapeutics Inc. Common Stock trades at $13.45 (market cap $6.04B). The key difference: Iovance Biotherapeutics Inc. Common Stock is far larger — about 4.3× Coursera Inc's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Coursera Inc for 47 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| COUR | IOVA | |
|---|---|---|
Market Cap | $1.39B | $6.04B |
Volume | 9,728,980 | 14,805,993 |
Sector | Consumer Staples | Health |
52-Week High | $10.73 | $14.82 |
52-Week Low | $4.64 | $1.81 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | $648.49M | $5.97B |
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.11, down 0.2% on the day, with a bearish technical signal and neutral oscillators. Revenue has grown from $524M in 2022 to $757.5M in 2025, but the company remains unprofitable with a net loss of $51M in 2025. Recent news highlights AI platform developments and significant institutional buying interest.
The stock offers potential upside to the $7.40 analyst consensus target but faces risks from persistent losses and competitive pressures. Positive cash flow and subscriber growth are key strengths, yet profitability challenges and integration costs from recent acquisitions present headwinds for near-term performance.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →